Moderna (NASDAQ:MRNA) Receives “Sector Perform” Rating from Royal Bank of Canada

Royal Bank of Canada restated their sector perform rating on shares of Moderna (NASDAQ:MRNA) in a report issued on Tuesday morning,Benzinga reports. Royal Bank of Canada currently has a $40.00 target price on the stock.

Several other equities analysts also recently weighed in on the company. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and lowered their target price for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Monday, November 18th. Berenberg Bank lifted their target price on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research report on Thursday, January 16th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Finally, Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $61.58.

Moderna Price Performance

NASDAQ MRNA opened at $35.72 on Tuesday. The company has a market capitalization of $13.75 billion, a PE ratio of -6.14 and a beta of 1.59. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The business’s fifty day moving average is $38.61 and its 200 day moving average is $53.82. Moderna has a fifty-two week low of $29.25 and a fifty-two week high of $170.47.

Insider Transactions at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Moderna

Several large investors have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company’s stock worth $776,075,000 after acquiring an additional 1,282,469 shares during the last quarter. State Street Corp increased its stake in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Theleme Partners LLP increased its stake in Moderna by 1.0% during the fourth quarter. Theleme Partners LLP now owns 7,306,861 shares of the company’s stock worth $303,819,000 after acquiring an additional 72,028 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Moderna by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company’s stock valued at $300,219,000 after buying an additional 171,774 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after buying an additional 906,114 shares during the period. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.